Shares of Boston Scientific surged 8.3% to $49.90 Wednesday morning after the medical-device maker delivered a Q2 earnings surprise and paired it with an aggressive restructuring blueprint — a one-two punch aimed at convincing investors the worst of a brutal 2026 selloff may be over.
• The Numbers Beat Expectations, but the Bar Was Low. Adjusted earnings came in at $0.86 per share, topping the $0.83 Wall Street consensus.
Revenue of $5.44 billion also cleared the $5.38 billion analysts expected. That matters because the stock entered this report battered — shares had fallen over 50% year-to-date after management repeatedly cut guidance. The beat breaks a cycle of diminishing confidence, but investors should note the market was expecting just 5.9% year-over-year revenue growth, a sharp deceleration from the 22.8% increase in the year-ago quarter.
• A Massive Restructuring Signals the Company Is Playing Defense. The restructuring plan, running through 2029, will cost $700–$800 million in pre-tax charges but aims to cut $500 million in annual expenses.
It will involve job cuts alongside new hires in growth areas.
Much of the savings will be reinvested into growth initiatives rather than returned to shareholders — a signal that management sees this as offense, not retreat, but shareholders won't see a profit-margin payoff for years.
• The Watchman Slowdown Remains the Elephant in the Room. The stock's collapse from its $109.50 September 2025 peak traces directly to problems with the company's flagship heart-implant device, used to reduce stroke risk. Management lowered guidance for the device, expecting U.S. sales to stay flat rather than grow at the mid-to-high single-digit pace previously forecast.
Rivals including Abbott, Bristol Myers Squibb, and Johnson & Johnson are closing in with competing products. Until Watchman stabilizes, the growth narrative stays under pressure.
• Analysts Still See Deep Upside — If Execution Follows. Boston Scientific carries 26 Buy ratings and zero Sells, with a consensus target near $72.25 — implying roughly 57% upside.
The P/E ratio of about 19x sits well below its five-year median of nearly 68x. The valuation screams cheap if restructuring savings materialize on schedule and the heart-device business finds a floor. That's a big "if" with a three-year execution horizon.